HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
Key Details
- 1FDA grants 510(k) clearance to HeartLung Corporation's AI-CVD algorithm.
- 2AI-CVD performs 11 opportunistic screening assessments on chest CT scans.
- 3Assesses for findings like coronary calcium, valve and wall calcium, volumetry, lung and liver attenuation, bone mineral density, and more.
- 4Alerts doctors to incidental findings that may indicate risk for conditions such as heart disease, stroke, osteoporosis, diabetes, and liver steatosis.
- 5Can be used for both new and prior CT scans, supporting broader preventive care.
- 6Platform potentially applicable to nearly 40 million CT scans per year in the U.S.
Why It Matters
This clearance introduces the most comprehensive FDA-cleared AI platform for opportunistic screening on CT, enabling earlier identification of at-risk patients and broadening the utility of routine imaging for preventive care. Radiology practices may see an expanded role in population health management through automated, multi-disease detection.
Source
Cardiovascular Business
Related News
•AuntMinnie
LLM Boosts Terminology Expansion in Radiology Reports Over RadLex
A large language model (LLM) significantly outperforms RadLex in expanding terms for radiology report language standardization.
•Radiology Business
Google Releases MedGemma 1.5 and MedASR AI Models for Medical Imaging
Google has launched MedGemma 1.5 and MedASR, two new open-access AI models tailored for healthcare and medical imaging use cases.
•AuntMinnie
Deep Learning AI Outperforms Radiologists in Detecting ENE on CT
A deep learning tool, DeepENE, exceeded radiologist performance in identifying lymph node extranodal extension in head and neck cancers using preoperative CT scans.